327 related articles for article (PubMed ID: 15896100)
1. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy.
Blais L; Sheehy O; St-Hilaire JM; Bernier G; Godfroid P; LeLorier JJ
Pharmacoeconomics; 2005; 23(5):493-503. PubMed ID: 15896100
[TBL] [Abstract][Full Text] [Related]
2. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy.
Chaisewikul R; Privitera MD; Hutton JL; Marson AG
Cochrane Database Syst Rev; 2001; (1):CD001901. PubMed ID: 11279737
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the cost-effectiveness of treatment for refractory partial epilepsy: a simulation model for pregabalin and levetiracetam].
Díaz S; Argumosa A; Horga de la Parte JF; Vera-Llonch M; Dukes E; Rejas-Gutiérrez J
Rev Neurol; 2007 Oct 16-31; 45(8):460-7. PubMed ID: 17948211
[TBL] [Abstract][Full Text] [Related]
4. Economic Evaluation of Add-on Levetiracetam for the Treatment of Refractory Partial Epilepsy in Korea.
Suh GH; Lee SK
Psychiatry Investig; 2009 Sep; 6(3):185-93. PubMed ID: 20046394
[TBL] [Abstract][Full Text] [Related]
5. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy.
Vera-Llonch M; Brandenburg NA; Oster G
Epilepsia; 2008 Mar; 49(3):431-7. PubMed ID: 17822431
[TBL] [Abstract][Full Text] [Related]
7. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
Ben-Menachem E; Gilland E
Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study.
Betts T; Yarrow H; Greenhill L; Barrett M
Seizure; 2003 Apr; 12(3):136-40. PubMed ID: 12651077
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
Li S; Cao J; Xiao N; Cai F
J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
[TBL] [Abstract][Full Text] [Related]
12. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.
Kinirons P; McCarthy M; Doherty CP; Delanty N
Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis.
Cotton BA; Kao LS; Kozar R; Holcomb JB
J Trauma; 2011 Aug; 71(2):375-9. PubMed ID: 21825941
[TBL] [Abstract][Full Text] [Related]
14. Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials.
Uthman BM; Almas M; Emir B; Giordano S; Leon T
Curr Med Res Opin; 2011 Jul; 27(7):1285-93. PubMed ID: 21561392
[TBL] [Abstract][Full Text] [Related]
15. Assessment of a dose-response relationship of levetiracetam.
Meencke HJ; Buyle S
Eur J Neurol; 2006 Sep; 13(9):942-6. PubMed ID: 16930358
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy.
Specchio LM; Boero G; Specchio N; De Agazio G; De Palo A; de Tommaso M; Beghi E; La Neve A
Seizure; 2006 Mar; 15(2):112-6. PubMed ID: 16406697
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of levetiracetam: a review of three pivotal clinical trials.
Privitera M
Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123
[TBL] [Abstract][Full Text] [Related]
18. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy.
Leppik I; Morrell M; Godfroid P; Arrigo C
Epilepsia; 2003 Oct; 44(10):1350-2. PubMed ID: 14510829
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on levetiracetam in epilepsy.
Lyseng-Williamson KA
CNS Drugs; 2011 Oct; 25(10):901-5. PubMed ID: 21936590
[TBL] [Abstract][Full Text] [Related]
20. [Experience with levetiracetam in childhood epilepsy].
Neuwirth M; Saracz J; Hegyi M; Paraicz E; Kollár K; Móser J; Rosdy B; Herczegfalvi A; Fogarasi A
Ideggyogy Sz; 2006 May; 59(5-6):179-82. PubMed ID: 16786712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
